Lloyd Larissa, Nicholson Calum, Strange Geoff, Cordina Rachael, Celermajer David S, Cheung Michael M H
Clinical Research Group, Heart Research Institute, Sydney, NSW, Australia.
Cardiology Department, Royal Prince Alfred Hospital, Sydney, NSW, 2050, Australia.
Int J Cardiol Congenit Heart Dis. 2025 Mar 25;20:100579. doi: 10.1016/j.ijcchd.2025.100579. eCollection 2025 Jun.
To compare the outcomes for repaired tetralogy of Fallot and Fontan patients who must travel from regional Victoria and interstate, in order to receive specialist congenital heart disease (CHD) surgery and ongoing care, with those of local patients.
This retrospective study included 332 patients who underwent tetralogy of Fallot (ToF) repair and 159 patients who underwent a Fontan procedure at Royal Children's Hospital (RCH) Melbourne between 2003 and 2017. Data was obtained from the National CHD Registry, linked with National Death Index data, and follow-up data from the Australian and New Zealand Fontan Registry.
Equivalent outcomes were observed between location groups in both cohorts for all of the main outcomes of interest. Repaired ToF subjects were aged 0.76 years (IQR 0.52-3.33) at operation and 10.2 years (IQR 5.46-14.9) at last follow-up, whilst Fontan subjects were aged 4.94 (IQR 4.27-5.66) years at operation and 14.2 years (IQR 11.3-16.4) at last follow-up. Mortality rates were extremely low and did not significantly differ between geographic groups, with 10-year survival in the repaired ToF cohort 98.0 % in the City group, 98.1 % in the Regional group, and 98.8 % in the Interstate group; and 97.8 %, 92.3 %, and 97.5 % in the Fontan cohort, respectively.
In the Australian setting and with adequate planning and local follow-up options, patients travelling from regional areas or interstate for their CHD operations have similar outcomes, out to 21 years, compared to patients living locally.
比较来自维多利亚州地区及州际的法洛四联症修复患者和Fontan手术患者(他们必须前往这些地方接受先天性心脏病(CHD)专科手术及后续护理)与本地患者的治疗结果。
这项回顾性研究纳入了2003年至2017年间在墨尔本皇家儿童医院(RCH)接受法洛四联症(ToF)修复手术的332例患者以及接受Fontan手术的159例患者。数据来自国家CHD注册中心,并与国家死亡索引数据以及澳大利亚和新西兰Fontan注册中心的随访数据相关联。
在两个队列的所有主要关注结果方面,不同地点组之间观察到了相似的结果。接受ToF修复手术的患者手术时年龄为0.76岁(四分位间距0.52 - 3.33),最后一次随访时为10.2岁(四分位间距5.46 - 14.9);而接受Fontan手术的患者手术时年龄为4.94岁(四分位间距4.27 - 5.66),最后一次随访时为14.2岁(四分位间距11.3 - 16.4)。死亡率极低,不同地理组之间无显著差异,ToF修复队列中,城市组10年生存率为98.0%,地区组为98.1%,州际组为98.8%;Fontan队列中分别为97.8%、92.3%和97.5%。
在澳大利亚的情况下,通过充分的规划和本地随访选择,从地区或州际前来接受CHD手术的患者与本地患者相比,在长达21年的时间里有相似的治疗结果。